DexCom, Inc. (NASDAQ:DXCM) – Equities researchers at Jefferies Group lifted their FY2017 EPS estimates for DexCom in a research report issued to clients and investors on Wednesday. Jefferies Group analyst R. Denhoy now expects that the medical device company will earn ($0.62) per share for the year, up from their previous estimate of ($0.67). Jefferies Group has a “Buy” rating and a $91.00 price target on the stock. Jefferies Group also issued estimates for DexCom’s Q1 2018 earnings at ($0.24) EPS, Q2 2018 earnings at ($0.11) EPS, Q3 2018 earnings at ($0.05) EPS, Q4 2018 earnings at $0.04 EPS and FY2018 earnings at ($0.37) EPS.

Other analysts also recently issued reports about the company. Piper Jaffray Companies reaffirmed a “buy” rating and set a $78.00 price target on shares of DexCom in a report on Wednesday, July 12th. Wedbush reiterated an “outperform” rating and set a $76.00 target price (down previously from $85.00) on shares of DexCom in a research report on Thursday, September 28th. Oppenheimer Holdings, Inc. set a $92.00 price target on DexCom and gave the stock a “buy” rating in a report on Wednesday, August 2nd. BMO Capital Markets restated an “outperform” rating and issued a $62.00 price target (down previously from $90.00) on shares of DexCom in a report on Thursday, September 28th. Finally, Northland Securities cut DexCom from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $85.00 to $60.00 in a report on Thursday, September 28th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $70.69.

ILLEGAL ACTIVITY NOTICE: “FY2017 Earnings Forecast for DexCom, Inc. (DXCM) Issued By Jefferies Group” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/fy2017-earnings-forecast-for-dexcom-inc-dxcm-issued-by-jefferies-group/1687308.html.

Shares of DexCom (NASDAQ DXCM) opened at $50.11 on Monday. DexCom has a one year low of $42.62 and a one year high of $88.80. The company has a debt-to-equity ratio of 0.84, a current ratio of 5.86 and a quick ratio of 5.50.

In other DexCom news, EVP Richard Doubleday sold 1,635 shares of DexCom stock in a transaction that occurred on Monday, October 23rd. The shares were sold at an average price of $44.82, for a total transaction of $73,280.70. Following the transaction, the executive vice president now directly owns 65,049 shares in the company, valued at approximately $2,915,496.18. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Andrew K. Balo sold 3,244 shares of DexCom stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $71.18, for a total transaction of $230,907.92. The disclosure for this sale can be found here. In the last 90 days, insiders sold 23,208 shares of company stock worth $1,597,567. 1.70% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of DXCM. Advisor Group Inc. grew its position in DexCom by 104.9% during the 2nd quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock worth $119,000 after purchasing an additional 837 shares in the last quarter. IFP Advisors Inc grew its position in DexCom by 30.5% during the 2nd quarter. IFP Advisors Inc now owns 2,431 shares of the medical device company’s stock worth $178,000 after purchasing an additional 568 shares in the last quarter. Toronto Dominion Bank grew its position in DexCom by 251.0% during the 3rd quarter. Toronto Dominion Bank now owns 3,647 shares of the medical device company’s stock worth $178,000 after purchasing an additional 2,608 shares in the last quarter. Independent Portfolio Consultants Inc. grew its position in DexCom by 0.4% during the 2nd quarter. Independent Portfolio Consultants Inc. now owns 2,499 shares of the medical device company’s stock worth $183,000 after purchasing an additional 9 shares in the last quarter. Finally, Janney Montgomery Scott LLC boosted its stake in shares of DexCom by 9.2% during the 2nd quarter. Janney Montgomery Scott LLC now owns 2,959 shares of the medical device company’s stock valued at $216,000 after buying an additional 250 shares during the period.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.